Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
February 19 2021 - 9:00AM
Business Wire
- Educational resources help
caregivers of the estimated 2.4 million people living with
dementia-related hallucinations and delusions identify and discuss
symptoms
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the
launch of MoreThanMemoryLoss.com, a new website with educational
resources designed to help caregivers and people living with
dementia to learn more about dementia-related hallucinations and
delusions.
“As a leading, national caregiver organization, we hear from
dementia caregivers every day about the challenges they experience
caring for loved ones with behavioral symptoms of dementia. This
new resource provides information and support to address these
symptoms that can have a devastating impact on families,” said John
Schall, Chief Executive Officer, Caregiver Action Network.
MoreThanMemoryLoss.com was developed following extensive
caregiver research and input from advocacy organizations. The site
offers educational and actionable resources for visitors, including
a doctor discussion guide, a dementia-related hallucinations and
delusions fact sheet and an adapted personal story from a caregiver
coping with a loved one’s experience of these symptoms.
Dementia affects 8 million people in the U.S. and its prevalence
is expected to increase as the population ages.1-4 Approximately 30
percent, or 2.4 million people in the U.S., experience
dementia-related psychosis and only half of them, or 1.2 million,
are diagnosed.1,5 Symptoms of dementia-related psychosis include
hallucinations, when someone experiences things that are not there,
such as seeing or hearing things that others do not and delusions,
when someone believes things that are not true, such as people are
talking about you (paranoia), or fear that someone is stealing from
you. These symptoms are also very distressing for family and
caregivers and may be associated with increased risk of aggressive
behavior in dementia patients.6 Hallucinations and delusions can
cause a person to lose touch with reality, and their loved ones to
lose touch with them.
“Caregivers often believe their job is to protect the image of
their loved one and to hide the symptoms of dementia-related
psychosis from others,” said Charmaine Lykins, Senior Vice
President, Global Product Planning and Chief Marketing Officer, at
Acadia Pharmaceuticals. “MoreThanMemoryLoss.com is an educational
resource dedicated to providing caregivers with information and
tools needed to start important conversations about
dementia-related hallucinations and delusions with their loved
one’s healthcare providers.”
Visit https://www.morethanmemoryloss.com to learn more, and sign
up for additional educational resources.
About Dementia-Related Psychosis
Approximately 8 million people in the United States are living
with dementia, a condition with a core feature of declining
cognition (changes in memory, decision-making abilities, language,
etc.) resulting in functional impairment. Dementia is a
manifestation of an underlying condition which is often progressive
and neurodegenerative in nature.7 In addition to cognitive decline,
dementing illnesses almost universally lead to neuropsychiatric
symptoms, including hallucinations, delusions, and changes in
behavior.
It is estimated that 2.4 million Americans (or 30% of people
with dementia) experience dementia-related hallucinations and
delusions. These symptoms may be frequent and severe and may recur
over time. A hallucination is defined as a perception-like
experience that occurs without an external stimulus and is sensory
(seen, heard, felt, tasted, sensed) in nature. A delusion is
defined as a false, fixed belief that is resolutely held despite
evidence to the contrary. Dementia-related psychosis occurs in many
types of dementia, including Alzheimer’s disease, dementia with
Lewy bodies, Parkinson’s disease dementia, vascular dementia, and
frontotemporal dementia. Serious consequences have been associated
with psychosis in patients with dementia, such as repeated hospital
admissions, increased likelihood of nursing home placement,
progression of dementia, and increased risk of morbidity and
mortality.8
About Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate
life. For more than 25 years we have been working at the forefront
of healthcare to bring vital solutions to people who need them
most. We developed and commercialized the first and only approved
therapy for hallucinations and delusions associated with
Parkinson’s disease psychosis. Our late-stage development efforts
are focused on dementia-related psychosis, negative symptoms of
schizophrenia and Rett syndrome, and in early-stage clinical
research we are exploring novel approaches to pain management, and
cognition and neuropsychiatric symptoms in central nervous system
disorders. For more information, visit us at www.acadia-pharm.com
and follow us on LinkedIn.
References
1Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia
in the United States: the aging, demographics, and memory study.
Neuroepidemiology. 2007;29(1-2):125-132. 2Goodman RA, Lochner KA,
Thambisetty M, et al. Prevalence of dementia subtypes in United
States Medicare fee—for—service beneficiaries, 2011—2013.
Alzheimers Dement. 2017;13(1):28—37. 3Hebert LE, Weuve J, Scherr
PA, et al. Alzheimer disease in the United States (2010-2050)
estimated using the 2010 census. Neurology. 2013;80(19):1778-1783.
4Alzheimer’s Association. 2020 Alzheimer’s disease facts and
figures. Alzheimer’s Dement. 2020;16(3):391-485 52017 Alzheimer’s
Disease Facts and Figures and Acadia market research. 6Lopez O, et
al. Psychiatric symptoms vary with the severity of dementia in
probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci.
2003;153:346-353. 7Dementia. (2019, September 19). Retrieved from
https://www.who.int/news-room/fact-sheets/detail/dementia. 8Connors
MH et al. Am J Geriatr Psychiatry 2018;26(3). Peters ME et al. Am J
Psychiatry 2015;172(5). Haupt M et al. Int J Geriatr Psychiatry
1996;11(11). Naimark D et al. J Am Geriatr Soc 1996;44(3). Stern Y
et al. Neurology 1994;44(12).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210219005133/en/
Acadia Pharmaceuticals Inc. Deb Kazenelson 818-395-3043
media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024